Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05163158
Other study ID # CENTRAL-CKD Protocol Version 1
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 24, 2022
Est. completion date December 31, 2025

Study information

Verified date August 2023
Source Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Contact Guylaine Marcotte
Phone 1(514)338-2222
Email guylaine.marcotte@cnmtl.gouv.qc.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Emerging data favors aortic blood pressure (BP) over brachial cuff BP in predicting CV and renal complications, as this BP directly impacts the heart, brain and kidneys. In parallel, central BP measuring devices have been developed that are more accurate towards aortic BP and easy to use without training. In no other condition than advanced chronic kidney disease (CKD) is BP control as important, since undertreatment is associated with adverse CV events and progression towards end-stage kidney disease (ESKD), while overtreatment similarly leads to adverse CV events and injurious falls but also acute kidney injury which can precipitate ESKD. To this day, standard BP management relies on brachial cuff BP, which is an imprecise surrogate marker of aortic BP, more so in the advanced CKD population. Considering that these patients have a high risk of CV morbidity and mortality and is a group where brachial BP may be the least reliable, it can be beneficial to manage hypertension in this population using central BP measurements. With the development of affordable and easy to use central BP devices, routine use of central BP in hypertension would now become a reality. However, the superiority of central BP to traditional brachial cuff BP in regard to clinical outcomes will first need to be demonstrated. Objectives: To demonstrate that targeting central BP in advanced CKD patients as opposed to brachial cuff BP is feasible and results in lower arterial stiffness after 12 months of follow-up. Methods: The CENTRAL-CKD trial is an investigator-initiated prospective parallel-group 1:1 randomized double-blinded multicenter pragmatic pilot trial. Patients with CKD stages 4 and 5 (n=116) will be randomized to either a central systolic BP target < 130 mmHg (intervention) or brachial systolic BP target < 130 mmHg (standard care). Central and brachial BP will be concomitantly measured, with treating physicians, patients and investigators blinded towards allocation. As this trial is of a pragmatic design, all other aspects of BP and CKD management, including anti-hypertensive treatment-related decisions, diastolic BP targets, and clinical and laboratory follow-ups will be at the discretion of the attending Nephrologist. The primary outcomes include feasibility of large-scale trial using prespecified criteria and aortic stiffness (carotid-femoral pulse wave velocity) at 12 months. Other cardiovascular, renal, quality of life and safety outcomes will be evaluated. Importance: CENTRAL-CKD is designed as a pilot trial aimed at providing the framework and justification to proceed to a large-scale trial with adequate power to detect the impact of the proposed intervention on clinically important outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 116
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Over 18 years of age; 2. eGFR <30 mL/min/1.73m2 as determined by the CKD-EPI equation (within 30 days of screening); 3. Office brachial cuff systolic blood pressure between 120 and 160 mmHg (using automated office blood pressure). Exclusion Criteria: 1. Already taking 5 or more anti-hypertensive medications (any class) 2. Unwillingness to change anti-hypertensive medication by the attending Nephrologist or patient 3. Recent acute kidney injury (>50% increase in serum creatinine in preceding 30 days) 4. Previous kidney replacement therapy (kidney transplant, hemodialysis or peritoneal dialysis) 5. Recent myocardial infarction, stroke, heart failure (in preceding 30 days) 6. Recent injurious fall requiring hospitalisation (in preceding 30 days) 7. Concomitant major illness / comorbidity that may result in death in the next 6 months 8. Participation in another study that is likely to affect BP levels 9. Inability to provide consent due to cognitive impairment.

Study Design


Intervention

Other:
Central vs brachial systolic blood pressure targeting
Participants will be randomized to either a central BP target (intervention) or a brachial BP target (standard care). For each group, the source of the BP (central or brachial) will be blinded and only the BP values will be provided to the attending Nephrologist. In both cases, the target SBP will be <130 mmHg.

Locations

Country Name City State
Canada Hôpital du Sacré-Coeur de Montréal Montréal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Progression towards kidney failure (sustained eGFR loss = 40%, kidney replacement therapy initiation or death from renal failure) 12 months
Other Major adverse cardiovascular adverse events (cardiovascular mortality, myocardial infarction, stroke, heart failure requiring hospitalisation, peripheral artery disease requiring revascularisation or amputation) Composite and individuals outcomes 12 months
Other All-cause hospitalisation 12 months
Other All-cause mortality 12 months
Other Acute kidney injury (>50% increase in serum creatinine) 12 months
Other Symptomatic orthostatic hypotension, dizziness, light headedness, injurious falls, syncope or any unexpected event attributable to the intervention 12 months
Primary Feasibility: Consent rate Proportion of participants who provide consent relative to the number approached for participation.
Feasibility criteria (No / Probable / Yes): <30% / 30-60% / >60%
Baseline
Primary Feasibility: Recruitment rate Proportion of randomized participants relative to the number of screened participants.
Feasibility criteria (No / Probable / Yes): <40% / 40-80% / >80%
Baseline
Primary Feasibility: Achieved BP target rate Proportion of randomized participants who achieve BP target at 12 months Feasibility criteria (No / Probable / Yes): <30% / 30-60% / >60% 12 months
Primary Feasibility: Completion rate Proportion of randomized participants who complete the trial Feasibility criteria (No / Probable / Yes): <40% / 40-80% / >80% 12 months
Primary Feasibility: Recruitment pace Number of participants recruited after 24 months of activation for all sites Feasibility criteria (No / Probable / Yes): <54 / 54-81 / >81 12 months after activation of last site
Primary Feasibility: Divergent treatment decision rate Proportion of divergent treatment decision based on central BP compared to brachial BP Feasibility criteria (No / Probable / Yes): <10% / 10-30% / >30% 12 months
Primary Feasibility: Therapeutic inertia rate Proportion of therapeutic inertia Feasibility criteria (No / Probable / Yes): >60% / 60-30% / <30% 12 months
Primary Difference in aortic stiffness Carotid-femoral pulse wave velocity 12 months
Secondary Difference in eGFR decline 12 months
Secondary Change in albuminuria 12 months
Secondary Difference in Daily Defined Doses of blood pressure drugs 12 months
Secondary Quality of life (KDQOL-SF questionnaire) Score 0 to 100. Higher score represents better quality of life 12 months
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A